Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. - Test2 - elhamkhani - TriplyDB

Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

http://www.wikidata.org/entity/Q43871660

about

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens Infection of semen-producing organs by SIV during the acute and chronic stages of the disease Challenges in initiating antiretroviral therapy in 2010.Quantification of antiretroviral drugs for HIV-1 in the male genital tract: current data, limitations and implications for laboratory analysis.HIV infection of the male genital tract--consequences for sexual transmission and reproduction.Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.HIV dynamics in seminal plasma during primary HIV infection HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitro The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.HIV pharmacology: barriers to the eradication of HIV from the CNS.Tissue reservoirs of HIV Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.Human prostate supports more efficient replication of HIV-1 R5 than X4 strains ex vivo.Antiretroviral bioanalysis methods of tissues and body biofluids.Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells.Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.Harnessing nanostructured systems for improved treatment and prevention of HIV disease

P2860

Q24799351-E248F360-E51A-4CED-BE58-EFEF9E476937 Q27301766-3A85EF5C-C0F2-4CE7-BD33-A70BD007B62E Q30227046-6EC4E5BD-EB97-4A62-95CF-BBF694CFD5C8 Q31135042-65F1E2CE-528A-4B57-95CD-72B28ECB77AA Q33629797-A6D516F4-B1A9-4640-9E66-C0936EF667FB Q33716348-1EB69B96-0328-4F57-88A2-286C5C30FA34 Q33786313-7826388F-8BD7-4BA8-9565-23FC7DAFE499 Q33807628-B91CE491-728F-4F1A-8134-FFC54CBD624D Q34083267-DAEF5CE1-ECD3-4E33-95E1-55F981D4A9AF Q34534986-4C230964-3446-4194-9554-C523307009FA Q35569867-0DA6FDB3-1F40-48E4-96AC-B9D0F897F2B6 Q36121190-4C9144A8-88DF-4C4A-B62F-B61075D750C0 Q36552753-8F02277C-7AE8-4F85-AF60-5BB86C2306CD Q37055454-4155ADD6-62AE-4090-B9BE-488D91A26823 Q37066971-E75CEEA4-6F2A-4195-AF00-B18AFA4D199B Q37112072-31EF788E-5A41-4683-9628-EBA89947C5A5 Q37332868-D4E5BCA0-4BC8-438D-BB1E-763418FE6173 Q37390163-EBADE7F8-6DF8-40A5-97D4-CD1709A6CE2B Q37394989-7F9BB991-B643-4DFA-B23B-EB5FD37E6DCE Q37425205-5AF0BCD9-EC47-4108-A39F-5F0E629DE831 Q38247035-1231F9A6-7605-4432-8D7C-6253BB5EDDBF Q41208022-DCAE6622-FBEC-4F73-855E-30F488AFD1C0 Q42931192-7351C892-7245-41BB-B155-217546D2F427 Q46374842-B8CE25B0-DBA6-4322-B668-55127A7B2ECB Q47624840-422B053D-80BA-4086-AFA5-4B849F014DB9 Q56992437-FE14B068-2F60-43B7-9346-0D205336F6C6

P2860

Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

http://www.wikidata.org/entity/Q43871660

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Differences in the detection o ...... tments: clinical correlations.

@en

Differences in the detection o ...... tments: clinical correlations.

@nl

type

label

Differences in the detection o ...... tments: clinical correlations.

@en

Differences in the detection o ...... tments: clinical correlations.

@nl

prefLabel

Differences in the detection o ...... tments: clinical correlations.

@en

Differences in the detection o ...... tments: clinical correlations.

@nl

P1433

Q43871660-6997FAAD-30D3-41F0-963A-E463A8DB6AA3

P1476

Q43871660-4EF7C135-F43B-4C4F-8BC4-C8C7EEE4495A

P2093

Q43871660-3B4CC97F-2FF9-41BB-B76F-1B7FFB355999

Q43871660-40482E2E-578E-4BA4-83C0-CCF4EFA26981

Q43871660-4B95617A-006E-462D-B549-05B20B1AF42B

Q43871660-93EDCC73-FF0C-4498-9D84-6299951B583D

Q43871660-9FF7810B-FBAF-4FF9-A056-1F9DC2C68CC1

Q43871660-C5AEA8E7-9F5F-4517-A142-D6367D99FB2F

P2860

Q43871660-08D5C016-D50D-4288-9505-169E0BD3ECB3

Q43871660-0F38D01B-5B3A-4DA6-9400-CBF9BA1F2EAE

Q43871660-1294F452-12A1-49EC-A6ED-D798FFD2B792

Q43871660-2325AC2E-EA80-470F-8BF6-E47FFB2116A4

Q43871660-26DDD139-FB63-4C11-862F-28064A712020

Q43871660-4E29471B-5A9C-43B4-A3BC-A6A41F447EC5

Q43871660-673AE13F-0A30-49AC-BE78-010325C13243

Q43871660-77FF77B8-60B5-46EF-B5D5-C0ED608F4236

Q43871660-844D181D-C58C-4B1B-8480-844A24FD808A

Q43871660-845FADA5-5037-49A4-AC93-5ADA14902D58

P304

Q43871660-C4131AE5-8151-4C6B-87BF-6AAE2C3CD517

P31

Q43871660-27BAAB71-DE37-48FB-A5F2-E9A4D99D50EF

P356

Q43871660-85E3E4BC-7D36-494E-B3D6-06E88F85B93D

P433

Q43871660-6BC2EE31-ABFA-4EEB-8C87-642F426B5DFC

P478

Q43871660-D9D99B1F-030F-432D-8EDA-E137E8FFE577

P577

Q43871660-43B240C2-48DC-4E3D-BCB5-1D768CDF5F75

P698

Q43871660-2E3EC15D-8F05-4424-AF61-7B265820245E

P356

WMWL-6W9Y-PXV2-X148

P1433

HIV Clinical Trials

P1476

Differences in the detection o ...... tments: clinical correlations.

@en

P2093

Alain Lafeuillade

http://www.w3.org/2001/XMLSchema#string

Bruno Lacarelle

http://www.w3.org/2001/XMLSchema#string

Caroline Solas

http://www.w3.org/2001/XMLSchema#string

Gilles Hittinger

http://www.w3.org/2001/XMLSchema#string

Philippe Halfon

http://www.w3.org/2001/XMLSchema#string

Stéphane Chadapaud

http://www.w3.org/2001/XMLSchema#string

P2860

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.

Antiretroviral drug concentrations in semen of HIV-1 infected men

Drug concentration heterogeneity facilitates the evolution of drug resistance.

Strategies for long-term success in the treatment of HIV infection.

Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.

Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy.

Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.

P304

27-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/WMWL-6W9Y-PXV2-X148

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11819183

http://www.w3.org/2001/XMLSchema#string